Immuno-Oncology | Specialty

FDA Grants Avelumab/Axitinib Combo Priority Review for RCC

February 12th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of avelumab and axitinib as a treatment for patients with advanced renal cell carcinoma.

Immuno-Oncology Expert Highlights How Steroid Dosage Influences Response

February 9th 2019

Different patterns of response are associated with the dosages of immunosuppressants used to manage the adverse effects of immunotherapies.

Dr. Subramanian on the Future of Immunotherapy in NSCLC

February 9th 2019

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at St. Luke’s Cancer Institute, discusses the future of immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer

February 7th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.

EU Panel Recommends Pembrolizumab/Chemo Combo in Squamous NSCLC

February 4th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer.

EU Panel Backs Frontline Atezolizumab Regimen in NSCLC

February 2nd 2019

The European Medicine’s Agency Committee for Medicinal Products for Human Use has recommended approval for the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Combos and Biomarkers Will Shape the Future of Bladder Cancer Immunotherapy

February 1st 2019

Although multiple checkpoint inhibitors have been introduced into the bladder cancer treatment paradigm during the past several years, their use in the malignancy remains an unfolding story.

FDA Expands Pemetrexed Approval for Frontline Pembrolizumab/Chemo Combo in NSCLC

January 31st 2019

The FDA has expanded the indication for pemetrexed in combination with pembrolizumab and platinum-based chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK alterations.

Dr. Socinski on Immunotherapy Approaches in Squamous NSCLC

January 30th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses combination versus single-agent immunotherapy in patients with squamous non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

January 28th 2019

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

January 27th 2019

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

January 26th 2019

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

January 26th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

BMS Withdraws Application for Nivolumab/Ipilimumab in TMB-High NSCLC

January 24th 2019

Bristol-Myers Squibb has withdrawn its supplemental biologics license application for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Evidence Grows for Earlier Immunotherapy in NSCLC

January 24th 2019

Clinical trial evidence is building for moving checkpoint blockade immunotherapy forward in the treatment timeline for non–small cell lung cancer, but improving patient selection for these therapies remains a key challenge.

Dr. Choueiri Discusses Immunotherapy in RCC

January 23rd 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Sabari Discusses Role of Immunotherapy in SCLC

January 18th 2019

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses the role of immunotherapy in the treatment of patients with small cell lung cancer.

Immunotherapy/Chemo Combinations Show Continued Benefit in NSCLC

January 17th 2019

Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.

Controversy Adds Caution to CRISPR Editing in United States

January 17th 2019

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

January 17th 2019

The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.